Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 6 of 6 entries
View as:

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT04767529 Org: User:
Start: 02/16/21 End: 05/02/24 Due: 05/02/25

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Phase: N/A Priority: Normal
NCT ID: NCT06528314 Org: User:
Start: 09/04/24 End: 10/31/29 Due: 10/31/30

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Phase: N/A Priority: Normal
NCT ID: NCT03976401 Org: User:
Start: 05/28/19 End: 01/10/22 Due: 01/10/23

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Phase: N/A Priority: Normal
NCT ID: NCT06161571 Org: User:
Start: 11/10/23 End: 10/31/26 Due: 10/31/27

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

Phase: N/A Priority: Normal
NCT ID: NCT05039450 Org: User:
Start: 07/30/21 End: 05/31/25 Due: 05/31/26

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT06215716 Org: User:
Start: 12/01/23 End: 11/30/32 Due: 11/30/33